دورية أكاديمية
أعرض في EDS

Tolerance and benefits of treatment for elderly patients with limited small-cell lung cancer.

التفاصيل البيبلوغرافية
العنوان: Tolerance and benefits of treatment for elderly patients with limited small-cell lung cancer.
المؤلفون: Janssen-Heijnen ML; Department of Research, Eindhoven Cancer Registry, Comprehensive Cancer Centre South, P.O. Box 231, 5600 AE, Eindhoven, The Netherlands; Department of Clinical Epidemiology, VieCuri Medical Centre, P.O. Box 1926, 5900 BX, Venlo, The Netherlands. Electronic address: research@viecuri.nl., Maas HA; Department of Geriatric Medicine, Tweesteden Hospital, P.O. Box 90107, 5000 LA, Tilburg, The Netherlands., Koning CC; Department of Radiation Oncology, Amsterdam Medical Centre, University of Amsterdam, P.O. Box 22660, 1100 DD, Amsterdam, The Netherlands., van der Bruggen-Bogaarts BA; Department of Pulmonary Diseases, VieCuri Medical Centre, P.O. Box 1926, 5900 BX, Venlo, The Netherlands., Groen HJ; Department of Pulmonary Diseases, University Medical Center Groningen, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands., Wymenga AN; Department of Medical Oncology, Medical Spectrum Twente, P.O. Box 50.000, 7500 KA, Enschede, The Netherlands.
المصدر: Journal of geriatric oncology [J Geriatr Oncol] 2014 Jan; Vol. 5 (1), pp. 71-7. Date of Electronic Publication: 2013 Sep 07.
نوع المنشور: Journal Article; Observational Study; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101534770 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-4076 (Electronic) Linking ISSN: 18794068 NLM ISO Abbreviation: J Geriatr Oncol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Amsterdam : Elsevier
مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Chemoradiotherapy, Adjuvant/*methods , Lung Neoplasms/*therapy , Small Cell Lung Carcinoma/*therapy, Aged ; Aged, 80 and over ; Chemoradiotherapy, Adjuvant/mortality ; Female ; Humans ; Lung Neoplasms/mortality ; Male ; Netherlands/epidemiology ; Registries ; Small Cell Lung Carcinoma/mortality
مستخلص: Objectives: Over 20% of all newly diagnosed Dutch patients with small-cell lung cancer (SCLC) are aged ≥75 years. Uncertainties still exist about safety and efficacy of chemotherapy and chemoradiation in elderly patients. We evaluated the association between patient characteristics and (completion of) treatment and also evaluated toxicity, response and survival in elderly patients with SCLC.
Materials and Methods: Population-based data from patients aged 75 years or older and diagnosed with limited SCLC in 1997-2004 in The Netherlands were used (N = 368). Additional data on co-morbidity, motive for deviating from guidelines, grades 3-5 toxicity, response and survival were gathered from medical records.
Results: Although only relatively fit elderly were selected for chemotherapy, almost 70% developed toxicity, leading to early termination of chemotherapy in over half of all patients. Median survival time was 6.7 months, but differed strongly according to type and completion of treatment (13.5 months for chemoradiation, 7.1 months for chemotherapy, 2.9 months for best supportive care, 11.5 months for patients receiving at least 4 cycles of chemotherapy and 3.6 months for less than 4 cycles).
Conclusion: Although toxicity rate was high and many patients could not complete the full chemotherapy, those who received chemotherapy or chemoradiation had a significantly better survival. We hypothesize that a better selection by proper geriatric assessments is needed to achieve a more favourable balance between benefit and harm.
(© 2013 Elsevier Ltd. All rights reserved.)
فهرسة مساهمة: Keywords: Elderly; Outcome; Population-based; Small-cell lung cancer; Survival; Treatment
تواريخ الأحداث: Date Created: 20140204 Date Completed: 20140926 Latest Revision: 20160519
رمز التحديث: 20221213
DOI: 10.1016/j.jgo.2013.07.008
PMID: 24484721
قاعدة البيانات: MEDLINE
الوصف
تدمد:1879-4076
DOI:10.1016/j.jgo.2013.07.008